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Kentucky.METHODS: Regression models were calculated to predict methamphet-
amine-related hospitalizations from 2010 county level Kentucky data. Explanatory
factors include PSE sales (in grams), number of clandestine lab incidents reported,
USDA urban/rural indicator, methamphetamine-related arrests, number of con-
trolled substance (CS) prescriptions dispensed, and population. Data sources in-
clude the Kentucky All Schedule Prescription Electronic Reporting Program, the
Kentucky Inpatient Discharge Data Set, the Kentucky State Policy Crime in Ken-
tucky Report, and Clandestine Laboratory Surveillance System. RESULTS: PSE sales
were not associated with methamphetamine-related hospitalizations in this
model. The number of clandestine lab incidents reported, however, has a strong
positive impact on methamphetamine-related hospitalizations (p0.001). Meth-
amphetamine-related arrests also have a strong positive relationship to hospital-
ization (p0.001). Finally, use of controlled substances has a small but negative
impact on methamphetamine-related hospitalization (p0.05). CONCLUSIONS:
PSE sales data alone cannot be used to predictmethamphetamine use as evidenced
by methamphetamine-related hospitalizations. The number of clandestine lab in-
cidents, however, reported is strongly associated with methamphetamine-related
hospitalizations. These findings suggest that policies aimed at reducing clandes-
tine labs may have a significant impact on indicators of methamphetamine use.
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COMPARISON OF TOTAL HEALTH CARE COSTS BETWEEN REMITTERS AND
NON-REMITTERS FOR SCHIZOPHRENIA PATIENTS FROM A PROSPECTIVE
LONGITUDINAL, OBSERVATIONAL STUDY IN THE PRESENCE OF MISSING DATA
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OBJECTIVES:Missing data has presented challenges to health economic analyses,
especially for a long-term observational study with repeated measures of clinical
and economic outcomes. The aim of this analysis was to compare the total health
care costs between symptom remission and non-remission from a long-term, ob-
servational study using mixed-effects models with and without multiple imputa-
tions (MI) of missing data. METHODS: Data (N2282) used for this analysis were
from a 3-year observational study of patients treated for schizophrenia in the
United States between July 1997 and September 2003. Costs of mental health ser-
vices were obtained at enrollment and at 6-month intervals during the 3-year
follow up. Cohorts of remitters versus non-remitters at enrollment were created
using established criteria. Total costs for remitters and non-remitters were com-
pared using mixed-effects models with and without MI based on Markov chain
Monte Carlo with multivariate normality assumption (MI-MCMC) or fully condi-
tional specification with predictive mean match method (MI-FCS). All analyses on
costs were adjusted for patient’s demographics and comorbidities. RESULTS: The
majority of the patients were male (61.6%) and non-remitters (73.8%) with a mean
age of 42 years. Out of 2282 patients, 41.2% had at least 1 visit (out of 7 visits) with
missing costs data. Without MI, the total healthcare costs were estimated to be
$8689.6 for the non-remitters and $6730.0 for the remitters with a difference of
$1959.7 (95% CI: $790 - $3129.4) over a 6-month period (p0.001). The estimated
differences in total costs between remitters and non-remitters were $1763.3 over
the 6-month period with the MI-MCMC method (p0.004) and $1483.9 with the
MI-FCS method (p0.009). CONCLUSIONS: Significant differences in total costs
between remitters and non-remitters were obtained from this study using mixed-
effects models with and without MIs. Further analysis will be conducted to explore
MI for estimation of other costs and examine missingness mechanisms.
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OBJECTIVES: To examine sources of error in claims-based adherence calculations
for LAI antipsychotics with potentially invalid days’ supply (DS) values and evalu-
ate the assumption that quantity-dispensed (QD) values are in product units.
METHODS: Pharmacy claims for single-dose LAI antipsychotics dispensed between
January 1, 2009 and December 31, 2010 were selected from a large US database.
Frequency distributions were generated for observed DS and QD values for each
product and dose. Observed QD values on premixed LAI antipsychotic claims were
divided by the product’s volume to test the assumption that QD was entered in
milliliters rather than units. After adjustment toQD for premixed LAI antipsychotic
claims, duration of therapy per injection was calculated for all LAI antipsychotics
as DS/QD. Calculated therapy duration was compared with the dosing interval in
the product’s package insert (PI). Percentage of claims with duration of therapy per
injection within the product’s PI range was calculated as a measure of the validity
of the observed DS value. RESULTS: For the 611,325 LAI antipsychotic claims ana-
lyzed, observed QD values ranged from 0.01 to 117, suggesting values that did not
always represent product units. After adjustment to QD for premixed LAI antipsy-
chotics, 98.5% of claims had an integer value for calculated quantity in product
units, supporting the assumption that premixed LAI antipsychotics’ quantities
were entered in milliliters. After adjustment, 21.5% of claims had a calculated
therapy duration per injection outside the PI range. Percentage of claims with
calculated therapy durations outside the PI ranged from 10.6% to 39.1% for pali-
peridone palmitate, 7.6% to 13.1% for risperidone long-acting injection, and 3.1% to
10.8% for olanzapine pamoate. CONCLUSIONS: Results raise concerns regarding
potentially invalid values in DS andQDfields. Algorithms for appropriate use of LAI
antipsychotic pharmacy claims in adherence calculations, quality measurement,
and cost analyses are recommended.
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OBJECTIVES: Uncertainty remains regarding the developmental courses of inat-
tentive (IN) and hyperactivity (HA) symptoms. Using group-based trajectory mod-
eling, we sought to identify distinct independent and joint IN/HA symptom trajec-
tories and their predictors. METHODS: A total of 1037 boys (mean age: 6.20.3
years) from low socioeconomic areas in Montreal were recruited in 1984 for the
Longitudinal and Experimental Study of Low Socioeconomic Status (SES) Boys in
Montreal. Teacher and mother ratings of subjects’ IN and HA symptoms were
collected annually at ages 6, and 10 to 15 using the Social Behavior Questionnaire,
where the higher of the two raters’ scores was taken as subject’s IN/HA score.
Numbers and probabilities of independent IN and HA trajectories were identified
using group-based semi-parametric mixture models. Joint IN/HA trajectories were
then constructed as the joint probabilities of independent IN/HA trajectories.
Multinomial logistic regressions were conducted to assess baseline parental and
subject behavioral problems as predictors of joint trajectories. RESULTS: Six and
five independent trajectories were generated for IN and HA symptoms, respec-
tively, constituting 30 joint trajectories. The most common independent IN trajec-
tory (29.5% of study sample) had a moderate number of IN symptoms at baseline
that increased slightly with age (moderate-slightly rising), whereas the most com-
mon independent HA trajectory (28.5%) was baseline moderate-sharply declining.
The most common joint trajectories were based on the co-occurrence of a moder-
ate-sharply rising IN trajectory, and a low-/moderate-slightly rising HA trajectory
(17% vs. 14%). Subjects’ aggressiveness, conduct-, oppositional-, and anti-social
problems (p0.001), and paternal SES (p0.01) were significant predictors of joint
trajectories. CONCLUSIONS: Group-based trajectory modeling may be a useful
time-dependent pattern recognition tool. It enabled the identification of distinct
independent and joint IN/HA trajectories in age-related developmental courses.
Assessing baseline behavioral problems and paternal SES may help identify and
target interventions for young boys at risk of high-level IN/HA symptoms early on.
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OBJECTIVES: To demonstrate a unique approach to modeling long-term time-on-
therapy and cardiovascular disease (CVD) outcomes of patientswith schizophrenia
treated with atypical antipsychotics (AAPs). METHODS: A 5-year Markov cohort
analysis among adult patients with schizophrenia was undertaken to compare
time-on-therapy and CVD outcome differences lurasidone, generic-olanzapine,
aripiprazole, quetiapine, and ziprasidone. Modeled health states were: patients on
initial AAP; patients switched to a second composite-AAP; and patients on clozap-
ine after failing a second composite-AAP. The composite-AAP health state simu-
lated frequent treatment switching and was operationalized by averaging out-
comes, costs, and discontinuation rates (for transition probabilities) of the AAPs.
Patients discontinuing composite-AAP due to lack of efficacy were switched to
clozapine. Time-on-therapy was modeled using sub-states based on time of
switching. Baseline characteristics of themodeled cohort, data for discontinuation
rates, and averageweight changewere obtained fromCATIE, a comparative clinical
trial of lurasidone vs quetiapine XR, and an open-label study comparing aripipra-
zole and olanzapine. Relative risk of diabetes obtained from a retrospective anal-
ysis predicted CVD events using Framingham BMI risk equations. RESULTS:Over 5
years, patient time-on-therapy for the initial-AAP, composite-AAP, and clozapine,
respectively, was 0.85, 3.13, 1.01 years (lurasidone); 1.00, 2.98, 1.02 (generic-olan-
zapine); 0.51, 3.41, 1.08 (aripiprazole); 0.47, 3.45, 1.08 (quetiapine); and 0.54, 3.37,
1.09 (ziprasidone). In a 10,000 patient cohort, there were 407, 434, 415, 416, and 412
CVD events, respectively, in the lurasidone, generic-olanzapine, aripiprazole, que-
tiapine, and ziprasidone arms. CONCLUSIONS: This long-term Markov cohort
model simulates multiple treatment switches by using a composite health state
from sub-states and also enabled outcome assessment of time-dependent patient
characteristics, such as CVD events. The results were consistent with published
Markovmicro-simulationmodels showing that lurasidone and generic-olanzapine
had favorable discontinuation rates and that lurasidone and ziprasidone had fewer
CVD events. This analysis represents an effective alternative for modeling cohort-
level outcomes.
PMH87
CROSS-CULTURAL ADAPTATION OF A RESEARCH VERSION OF THE REY
AUDITORY VERBAL LEARNING TEST (RAVLT) INTO (US) SPANISH
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OBJECTIVES: The Rey Auditory Verbal Learning Test (RAVLT) was developed to
evaluate verbalmemory. The standard form comprises a 15-word list (List A) learn-
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